. Author manuscript; available in PMC: 2014 Nov 1.

Published in final edited form as: Cancer Treat Rev. 2013 Mar 1;39(7):10.1016/j.ctrv.2013.01.008. doi: 10.1016/j.ctrv.2013.01.008

Table 3.

Dose escalation CFRT studies used as a benchmark for HFRT studies.

Reference	n	risk groups					BED (Gy), at α/β =		FFBF	RTOG late toxicity Grade ≥2 (%)
			median FU (months)	total dose (Gy or GyE)	total fractions	Gy/ fraction	1.5	10		GU	GI
MD Anderson / Kuban²	151	mostly low, intermediate	43.5	78	39	2	182	94	8-year Phoenix: 78% (p = 0.001)	8	26
	150			70	35	2	163	84	8-year Phoenix: 59% (p = 0.001)	13	13

Dutch / Al- Mamgani³	333	low, intermediate,	70	78	39	2	182	94	7-year ASTRO: 54% (p = 0.04) 7-year Phoenix: 56% (p = 0.03)	40	35
	331	high		68	34	2	159	82	7-year ASTRO: 47% (p = 0.04) 7-year Phoenix: 45% (p = 0.03)	41	25

MGH / Zietman^{4, 5}	195	low, intermediate,	66	79.2	44	1.8	174	93	5-year ASTRO: 80% (p < 0.001) 10-year ASTRO: 83% (p < 0.001)	21	19
	197	high		70.2	39	1.8	154	83	5-year ASTRO: 61% (p < 0.001) 10-year ASTRO: 68% (p < 0.001)	20	9

UK MRC / Dearnaley ⁶	63	low, intermediate,	64	74	37	2	173	89	5-year ASTRO: 71% (p = 0.1)	18	23
	64	high		64	32	2	149	77	5-year ASTRO: 59% (p = 0.1)	11	11

Abbreviations: ASTRO: American Society of Therapeutic Radiology and Oncology; BED: biologically equivalent dose; CFRT: conventionally fractionated radiotherapy; DM: distant metastasis; FFBF: freedom from biochemical failure; FU: follow-up; GI: gastrointestinal; GU: genitourinary; HFRT: hypofractionated radiation therapy; NS: not significant; NR: not reported; OS: overall survival